SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
LOS ANGELES, May 08, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) concerning possible violations of federal securities laws between May 1, 2012 and December 11, 2013 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 was going well and the share price was artificially inflated. When this news reached the public, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
